Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Kiora Pharmaceuticals, Inc.
eyegatepharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Kiora Pharmaceuticals secured funding through a private placement with institutional investors on April 3, 2026, issuing common stock and multiple warrant tranches to strengthen its capital base for biopharmaceutical development and operations.
Key Takeaways
Kiora issued 438,471 shares of common stock plus three separate warrant tranches totaling approximately 11.4 million shares
Pre-funded warrants carry a nominal $0.0001 exercise price while Tranche A warrants have a $1.94 exercise price, indicating significant dilution potential
2 more takeaways
Related Filings (2)
2 more filings from Kiora Pharmaceuticals, Inc. in the last 90 days